Please sign in to follow a disease.
Integumentary system disorder
MONDO:0002051A disease involving the integumental system.
Also known as: disease of integumental system, disease or disorder of integumental system, disorder of integumental system, integumental system disease, integumental system disease or disorder, integumentary disease, disorder of integument
3963 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
MRNA shingles vaccine trial ends early – what we know
⭐️ VACCINE ⭐️ TerminatedThis study tested several experimental mRNA vaccines against shingles in healthy adults aged 50 to 85. The goal was to check safety and immune response compared to the current shingles vaccine, Shingrix. The trial was terminated early, so results are limited, but the data may hel…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
New drug trial offers hope for Hard-to-Treat cancers
Disease control TerminatedThis early-stage study tests a new drug, PF-08046049/SGN-BB228, in people with advanced melanoma and other solid tumors that have spread or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. About 41 participants will ta…
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for painful skin condition: brensocatib enters phase 2b trial
Disease control TerminatedThis study tests whether brensocatib can reduce painful lumps and abscesses in people with moderate to severe hidradenitis suppurativa (HS). About 214 adults will receive either brensocatib or a placebo for 16 weeks. The goal is to see if the drug improves skin lesions and overal…
Phase: PHASE2 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Breast cancer drug showdown: which CDK4/6 inhibitor works best?
Disease control TerminatedThis phase 3 trial aimed to compare two drugs, ribociclib and palbociclib, in people with a specific type of advanced breast cancer (HR+/HER2- with HER2-enriched features). Participants received one of the drugs combined with hormone therapy. The goal was to see which combination…
Phase: PHASE3 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Laser plus gel: new hope for port wine stains?
Disease control TerminatedThis study tested whether adding timolol gel to pulsed dye laser treatment could improve results for port wine stains on children's faces. Twenty-five children aged 6 months to 18 years were enrolled, but the study was stopped early. The goal was to see if the combination led to …
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for HS sufferers: Long-Term drug trial shows promise
Disease control TerminatedThis study looks at the long-term safety and effectiveness of spesolimab for people with hidradenitis suppurativa (HS), a painful skin condition. Participants who completed a prior spesolimab study receive injections under the skin every 2 weeks for about 1.5 years. The goal is t…
Phase: PHASE2, PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental cell therapy takes on stubborn autoimmune diseases
Disease control TerminatedThis early study tested a new cell therapy called LUCAR-G79 in just 3 adults with severe autoimmune diseases that did not respond to standard treatments. The therapy uses specially engineered immune cells to target and potentially calm the overactive immune system. The main goals…
Phase: PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Eczema drug study halted early: what we learned about GSK1070806
Disease control TerminatedThis study was designed to check the long-term safety of an experimental drug called GSK1070806 for people with moderate to severe eczema (atopic dermatitis). It enrolled 79 adults who had already completed an earlier study of the same drug. The study was terminated early, so res…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising melanoma combo trial halted early – only one patient enrolled
Disease control TerminatedThis study tested a new drug called acasunlimab, given alone or with pembrolizumab, in people with advanced melanoma that had stopped responding to standard treatments. The trial was terminated early after enrolling only one participant, so no conclusions can be drawn about safet…
Phase: PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental combo for Hard-to-Treat cancers shows early promise but study halted
Disease control TerminatedThis early-phase trial tested a combination of two oral drugs, mirdametinib and brimarafenib, in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the best dose, and see if the combo could shrink tumors. Th…
Phase: PHASE1, PHASE2 • Sponsor: SpringWorks Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can an extra shot boost COVID protection in autoimmune patients?
Disease control TerminatedThis study tests whether an additional dose of a COVID-19 vaccine can improve immune protection in adults and children with autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis, and others who are taking immunosuppressive medications. Participants who had a we…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug aimed at regrowing hair in severe alopecia
Disease control TerminatedThis study tested a drug called amlitelimab in 166 adults with severe alopecia areata, a condition causing significant hair loss. Participants received either the drug or a placebo by injection. The main goal was to see if the drug could reduce hair loss scores after 36 weeks. Th…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Eye drop gel shows promise for skin graft healing, but trial stalls
Disease control TerminatedThis study tested whether applying 0.25% timolol gel (a beta-blocker eye drop used for glaucoma) to skin grafts could improve healing and appearance after skin cancer surgery. Researchers planned to enroll 82 patients but stopped early with only 10 participants. The goal was to s…
Phase: PHASE2, PHASE3 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Experimental combo therapy shows promise in advanced cancers, but trial halted early
Disease control TerminatedThis study tested whether injecting vidutolimod directly into tumors plus giving cemiplimab through a vein could shrink cancers that have spread. The trial included 77 people with several types of advanced cancer. Unfortunately, the study was stopped early, so we have less inform…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New cancer drug BBI-355 trial halted early – what we know
Disease control TerminatedThis early-phase trial tested a new oral drug called BBI-355, alone or with other targeted therapies, in people with advanced solid tumors that had extra DNA (oncogene amplifications). The study aimed to find the safest dose and check for side effects. It was terminated early, so…
Phase: PHASE1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Eczema drug trial halted early – what we know
Disease control TerminatedThis study tested an experimental drug called JNJ-95475939 in 256 adults with moderate to severe atopic dermatitis (eczema). The goal was to see if the drug could improve skin symptoms like redness, itching, and scaling better than a placebo. The trial was stopped early, so final…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New Two-Target antibody for eczema tested in early trial
Disease control TerminatedThis early-stage trial tested a new drug called NM26-2198, a bispecific antibody that blocks two inflammatory signals (IL-4R and IL-31) involved in atopic dermatitis (eczema). The study included 126 healthy volunteers and patients with moderate-to-severe eczema, receiving either …
Phase: PHASE1 • Sponsor: Yellow Jersey Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Cancer drug trial halted after just one patient
Disease control TerminatedThis phase 2 trial tested whether the immunotherapy drug atezolizumab could shrink head and neck skin cancers that had spread to lymph nodes before surgery. Only 1 person enrolled before the study was terminated early. The goal was to see if the drug could eliminate all cancer ce…
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Eczema drug trial halted midway – what happened?
Disease control TerminatedThis study tested an injectable drug called GSK1070806 in 161 adults with moderate to severe atopic dermatitis (eczema) who had already tried other treatments. The goal was to see if the drug could reduce eczema severity and itching compared to a placebo. However, the trial was t…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Melanoma drug combo trial halted early – only 5 patients enrolled
Disease control TerminatedThis study tested whether adding hydroxychloroquine (a malaria drug) to standard targeted therapy (dabrafenib and trametinib) could help control advanced melanoma that had spread or could not be removed by surgery. It was designed for people with a specific gene mutation (BRAF V6…
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Melanoma drug combo trial halted after just 3 patients
Disease control TerminatedThis study tested two drugs, encorafenib and binimetinib, given before surgery to people with stage IIIB-D melanoma that had spread to lymph nodes. The goal was to see if the drugs could shrink or eliminate the cancer before removal. The trial was stopped early after enrolling on…
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental pill shows early promise for painful skin condition
Disease control TerminatedThis pilot study tested the drug deucravacitinib against a placebo in people with moderate-to-severe hidradenitis suppurativa, a chronic skin condition causing painful lumps. Only 7 people enrolled before the study was stopped early. The goal was to see if the drug could reduce i…
Phase: PHASE2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immunotherapy combo tested for aggressive breast cancer – trial stopped early
Disease control TerminatedThis phase 3 trial tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy and HER2-targeted therapy could help people with HER2-positive breast cancer that has spread. The study enrolled 190 participants but was terminated early, so the full results ar…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Exosome hair loss study halted early – what we know
Disease control TerminatedThis study tested whether exosomes from donated stem cells could help people with hair loss. It was a small, early-phase trial with 16 participants, comparing treated areas to untreated ones. The study was terminated early, so results are limited. The goal was to see if the treat…
Phase: EARLY_PHASE1 • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Amniotic membrane wrap studied for stubborn leg sores in seniors
Disease control TerminatedThis study tested a special wrap made from donated placenta tissue (human amniotic membrane) to help heal difficult leg ulcers caused by poor blood flow in people aged 65 and older. The goal was to see if the wrap could close the wound completely within 12 weeks. The trial was st…
Phase: NA • Sponsor: BioLab Holdings • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Eczema drug switch studied after first treatment fails
Disease control TerminatedThis study looked at whether a drug called tralokinumab could help adults with eczema who had already tried dupilumab and didn't get enough relief. The plan was to treat 20 people for 24 weeks, but the study was stopped early and only 7 people took part. The main goal was to see …
Phase: PHASE4 • Sponsor: Psoriasis Treatment Center of Central New Jersey • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Discoid lupus drug trial halted midway
Disease control TerminatedThis study tested an experimental drug called daxdilimab in 72 adults with moderate-to-severe discoid lupus erythematosus, a skin condition that causes scarring and hair loss. The goal was to see if the drug could reduce disease activity compared to a placebo. However, the trial …
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Blood cancer transplant study tests safer GVHD prevention
Disease control TerminatedThis phase 2 trial tested two different drug combinations to prevent graft-versus-host disease (GVHD) in 150 people with blood cancers receiving a stem cell transplant from an unrelated donor. Both combinations used cyclosporine and sirolimus, plus either mycophenolate mofetil or…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental drug for rare skin disease fails to reach goal
Disease control TerminatedThis early-stage trial tested a drug called DS-2325a in 9 adults with Netherton syndrome, a rare genetic condition causing severe skin redness, scaling, and allergies. The study aimed to check safety and whether the drug could help control the disease. However, the trial was term…
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New pill shows promise for severe baldness, but trial cut short
Disease control TerminatedThis study tested a drug called KL130008 in 114 adults with severe alopecia areata, a condition causing major hair loss. The goal was to see if the drug could safely regrow hair, measured by how many people achieved 80% or more scalp coverage. However, the trial was terminated ea…
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cream aims to stop vitiligo relapse after repigmentation
Disease control TerminatedThis trial tested a cosmetic cream called RV5098A to see if it could help adults with vitiligo keep their facial pigmentation after successful repigmentation treatment. Vitiligo causes white patches on the skin, and even after treatment, about 40% of people lose color again withi…
Sponsor: Pierre Fabre Dermo Cosmetique • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Early trial of experimental cancer combo halted after just 6 patients
Disease control TerminatedThis early-phase study tested a new drug called PF-08046032, given alone or with another drug (sasanlimab), in adults with advanced lymphomas or solid tumors like lung cancer and melanoma. The trial aimed to check safety and find the right dose, but it was terminated early after …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Personalized mRNA cancer vaccine trial halted midway
Disease control TerminatedThis study tested a personalized mRNA vaccine (mRNA-4157) combined with the immunotherapy drug pembrolizumab for people with advanced but removable skin cancer (cutaneous squamous cell carcinoma). The goal was to see if the combination could prevent the cancer from coming back be…
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Eczema probiotic trial for kids ends early – too few participants
Disease control TerminatedThis study tested a probiotic supplement for children aged 6 months to 3 years with mild-to-moderate eczema. The goal was to see if the probiotic could reduce eczema severity and the need for steroid creams. However, the trial was terminated early and only enrolled 4 children, so…
Phase: NA • Sponsor: Bionou Research, S.L. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New daily pill aims to stop HAE attacks, but trial cut short
Disease control TerminatedThis phase 2 trial tested KVD824, an oral pill, to prevent swelling attacks in people with hereditary angioedema types I and II. The study planned to compare three doses against a placebo over several months. However, the trial was terminated early with only 33 participants, so t…
Phase: PHASE2 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental triple therapy for advanced cancers shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested the drug plinabulin combined with radiation and immunotherapy in 19 people with advanced cancers (like lung, bladder, or melanoma) that had stopped responding to standard immunotherapy. The goal was to see if the combination was safe and could shrink…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Promising cream for painful skin condition tested in tiny trial
Disease control TerminatedThis small, early trial tested a cream called ruxolitinib 1.5% on 6 people with early-stage hidradenitis suppurativa, a painful skin condition that causes lumps and abscesses. The goal was to see if the cream could reduce inflammation and improve symptoms after 16 weeks. However,…
Phase: PHASE2 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental pill aims to stop extra bone growth in rare disease
Disease control TerminatedThis phase 2 trial tested two doses of an oral drug called fidrisertib (IPN60130) in children and adults with fibrodysplasia ossificans progressiva (FOP), a rare condition where soft tissues turn into bone. The goal was to see if the drug could reduce new abnormal bone growth com…
Phase: PHASE2 • Sponsor: Clementia Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New gel shows promise for vitiligo, but study halted early
Disease control TerminatedThis study tested a gel called VYN201 for people with non-segmental vitiligo, a condition that causes white patches on the skin. The goal was to see if the gel could reduce the size of these patches over 24 weeks. The trial involved 205 adults aged 18 to 75, but it was terminated…
Phase: PHASE2 • Sponsor: Vyne Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Melanoma drug combo study halted before full results
Disease control TerminatedThis study tested a combination of two drugs, ipilimumab and epacadostat, in people with advanced melanoma that could not be removed by surgery or had spread. The goal was to see if adding epacadostat to standard treatment improved survival. However, the study was stopped early f…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cancer pill shows early promise, but trial halted
Disease control TerminatedThis early-stage trial tested an oral drug called TNO155, alone or with another drug (nazartinib), in 227 adults with advanced solid tumors like lung cancer, melanoma, and head/neck cancer. The main goal was to check safety and find the right dose. The study was terminated early,…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage trial tested an investigational drug called TransCon TLR7/8 agonist, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that could not be cured by surgery or radiation. The study aimed to find a safe dose and check for side effect…
Phase: PHASE1, PHASE2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Breast cancer radiation showdown: 3D vs internal implants
Disease control TerminatedThis study compared two types of radiation given after breast-conserving surgery for early-stage breast cancer: 3D conformal radiation (external beams) and internal brachytherapy (radioactive material placed in the breast). Only 6 women took part before the trial was stopped earl…
Phase: NA • Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Promising drug for hand and foot blisters falls short in early trial
Disease control TerminatedThis study tested a daily pill called deucravacitinib in 3 adults with palmoplantar pustulosis (PPP), a painful skin condition causing blisters on palms and soles. The goal was to see if the drug could reduce disease severity by at least 50% over 24 weeks. However, the trial was …
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Cold plasma zaps away Kids' skin lesions in new trial
Disease control TerminatedThis study tested a cold atmospheric plasma device on children aged 4-21 with warts or molluscum lesions. The device uses ionized gas to treat the lesions without heat. The trial was terminated early, so we don't have full results on how well it worked or its safety.
Phase: PHASE3 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
HIV pill combo fails to slim belly fat in early trial
Disease control TerminatedThis study tested whether switching to a two-drug HIV treatment (raltegravir plus maraviroc) could reduce belly fat (lipohypertrophy) in people whose HIV was already well-controlled. It included 48 adults on stable HIV therapy for at least 5 years. The study was stopped early, so…
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Promising drug for rare skin ulcers shows early potential
Disease control TerminatedThis study tested a drug called spesolimab in 5 adults with moderate to severe pyoderma gangrenosum, a rare autoimmune disease that causes painful skin ulcers. The goal was to see if the drug could help heal the ulcers and to understand how the body's immune system responds. The …
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Promising psoriasis drug trial halted early – what now?
Disease control TerminatedThis study tested a drug called imsidolimab for adults with generalized pustular psoriasis (GPP), a rare and painful skin condition. The trial aimed to see if the drug is safe and works over the long term. However, the study was terminated early, so we have less information than …
Phase: PHASE3 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental cancer combo shows early promise but study halted
Disease control TerminatedThis early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…
Phase: PHASE1 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental drug HZN-825 tested for rare scleroderma lung and skin damage
Disease control TerminatedThis trial tested an experimental drug called HZN-825 in about 300 people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that causes skin thickening and can damage the lungs. Participants took either a low dose, a high dose, or a placebo daily for 52 weeks. …
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Immune cell therapy tested for tough childhood cancers
Disease control TerminatedThis early-phase study tested a treatment using donated natural killer (NK) cells from cord blood, combined with chemotherapy, for children and young adults with solid tumors that returned or didn't respond to standard care. The goal was to find the safest dose and check for side…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for vitiligo: experimental drug aims to restore skin color
Disease control TerminatedThis study tested an experimental drug called MK-6194 in adults with non-segmental vitiligo, a condition that causes white patches on the skin. The goal was to see if the drug could safely reduce the amount of vitiligo on the face compared to a placebo. The trial was stopped earl…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Early trial of PF-08046031 for advanced cancers ends early
Disease control TerminatedThis early-stage study tested a new drug called PF-08046031 in 11 adults with advanced melanoma or other solid tumors that had spread or had no standard treatment options. The main goal was to check the drug's safety and side effects. The trial was terminated early, so its findin…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug combo targets brain metastases in advanced cancers
Disease control TerminatedThis study tested a combination of two drugs, bintrafusp alfa and pimasertib, in people whose cancer had spread to the brain. The goal was to find the safest dose and see if the treatment could slow or stop the cancer from growing. The trial was stopped early after enrolling only…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug hope for painful hand and foot pustules
Disease control TerminatedThis trial tested the drug deucravacitinib in people with moderate-to-severe palmoplantar pustulosis, a skin condition causing painful pustules on the palms and soles. The study planned to enroll 25 participants who would take the drug daily for 16 weeks, but it was terminated ea…
Phase: NA • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Hope for rare skin disease: new drug shows promise in trial
Disease control TerminatedThis study tested a medicine called spesolimab for people with Netherton syndrome, a rare genetic skin condition causing severe redness and scaling. About 43 people aged 12 and older took part, receiving either the drug or a placebo. The goal was to see if spesolimab could reduce…
Phase: PHASE2, PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Promising combo for tough leukemias hits snag: trial ends early
Disease control TerminatedThis phase II trial tested a combination of two drugs, venetoclax and decitabine, in 235 patients with certain blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) that had come back or not responded to treatment, as well as in older patien…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New Three-Drug cocktail takes on tough melanoma
Disease control TerminatedThis study tested whether a three-drug combination (encorafenib, binimetinib, and pembrolizumab) works better than a two-drug combo (ipilimumab and nivolumab) for people with advanced melanoma that has a BRAF mutation and has already been treated with anti-PD-1 therapy. The trial…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New synthetic skin patch tested for Hard-to-Heal wounds
Disease control TerminatedThis study tested a man-made skin substitute called Restrata for treating diabetic foot ulcers and venous leg ulcers. For diabetic foot ulcers, Restrata was compared to standard wound care. For venous leg ulcers, it was compared to a living cell-based skin substitute (Apligraf). …
Phase: NA • Sponsor: Acera Surgical, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug shows promise for blistering skin disease in extended trial
Disease control TerminatedThis study looks at the long-term safety of a drug called efgartigimod for adults with moderate-to-severe bullous pemphigoid, a condition that causes painful blisters. Participants who finished the main study can continue treatment for up to 48 weeks, with the option to pause and…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Experimental lymphoma drug ASTX660 tested in tiny, terminated trial
Disease control TerminatedThis early-phase trial tested the drug ASTX660 in just 8 people with T-cell lymphoma that had returned or not responded to prior treatments. The study aimed to find a safe dose and check for side effects, but it was stopped early. Because it was so small and incomplete, we cannot…
Phase: PHASE1, PHASE2 • Sponsor: Otsuka Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Promising combo for tough breast cancers hits early hurdle
Disease control TerminatedThis early-phase trial tested a combination of targeted drugs (neratinib, pertuzumab, trastuzumab) and chemotherapy (paclitaxel, doxorubicin, cyclophosphamide) in 34 people with advanced or inflammatory breast cancer. The goal was to find the best dose and see if the combo could …
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Experimental drug vixarelimab tested for two scarring lung diseases
Disease control TerminatedThis study tested the drug vixarelimab against a placebo in people with idiopathic pulmonary fibrosis (IPF) or systemic sclerosis-associated interstitial lung disease (SSc-ILD). The goal was to see if it could preserve lung function over 52 weeks. The trial was terminated early, …
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Promising cancer combo trial halted after just 2 patients
Disease control TerminatedThis early-phase study tested a radioactive drug called 225Ac-SSO110 combined with standard immune checkpoint inhibitors for people with advanced small cell lung cancer or Merkel cell carcinoma. The goal was to check safety and find the right dose. However, the trial was terminat…
Phase: PHASE1, PHASE2 • Sponsor: Ariceum Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New pill for chronic hives and skin disease tested – but study halted early
Disease control TerminatedThis study tested an oral drug called INF904 in people with moderate to severe chronic spontaneous urticaria (long-term hives) or hidradenitis suppurativa (a painful skin condition). The trial was open-label and lasted 28 days of treatment plus follow-up. It aimed to check safety…
Phase: PHASE2 • Sponsor: InflaRx GmbH • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental combo for skin cancer stalls as trial ends early
Disease control TerminatedThis early-phase trial tested a new drug (SAR444245) combined with an existing immunotherapy (cemiplimab) in 46 adults with advanced melanoma or squamous cell skin cancer that could not be surgically removed. The goal was to see if the combination shrank tumors. However, the stud…
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for painful skin condition: experimental drug shows promise
Disease control TerminatedThis study tested a new drug called amlitelimab for adults with moderate to severe hidradenitis suppurativa, a painful skin condition that causes boils and tunnels. About 90 people received either the drug or a placebo for 16 weeks, with an optional long-term extension. The goal …
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Gene therapy shot for dry AMD shows promise in early trial
Disease control TerminatedThis study tested a single injection of a gene therapy called GT005 in 98 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. The goal was to see if the treatment could slow the growth of damaged areas in the eye and c…
Phase: PHASE2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Gene therapy shot for dry AMD shows promise but trial halted early
Disease control TerminatedThis study tested a single injection of GT005, a gene therapy, in 255 people with geographic atrophy from dry age-related macular degeneration. The goal was to see if it could slow the growth of blind spots in the eye. The trial was terminated early, so we have less data than hop…
Phase: PHASE2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental gene injection targets dry AMD
Disease control TerminatedThis early-stage trial tested a gene therapy called GT005 for dry age-related macular degeneration (AMD), a leading cause of vision loss. The therapy delivers a working gene to the retina via a single injection. The study enrolled 56 people and focused on safety and dosing, but w…
Phase: PHASE1, PHASE2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Engineered virus takes on Hard-to-Treat melanoma
Disease control TerminatedThis early-stage trial tested a modified virus (VSV-IFNbetaTYRP1) in 12 patients with advanced melanoma that had spread or could not be removed by surgery. The virus was designed to infect and kill melanoma cells while also boosting the immune system's attack. The main goals were…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New lymphoma drug trial halted early
Disease control TerminatedThis study tested a new drug, PF-08046045, in 22 adults with advanced lymphomas (cancers of the immune system). The goal was to find a safe dose and check for side effects. The trial was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Hair loss ointment study halted early – only 4 people enrolled
Disease control TerminatedThis study tested a custom ointment called DPCP to help people with severe alopecia areata, a condition causing patchy or complete scalp hair loss. The goal was to see if the ointment could safely regrow hair. Only 4 people took part before the study was stopped early, so results…
Phase: PHASE3 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Experimental virus-antibody combo tested for tough skin cancers
Disease control TerminatedThis early-phase study tested a combination of two drugs—a virus-based therapy (talimogene laherparepvec) and an antibody (panitumumab)—in 5 people with advanced skin squamous cell carcinoma that had spread or come back. The main goals were to check safety and see if tumors shran…
Phase: PHASE1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Early-Stage lung blood pressure drug trial halted
Disease control TerminatedThis study tested the drug riociguat in people with early pulmonary vascular disease, a condition where blood vessels in the lungs narrow, making the heart work harder. The trial included 35 adults with connective tissue disease or an inherited form. Participants received either …
Phase: PHASE2 • Sponsor: Heidelberg University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New cancer drug OC-001 tested in advanced tumors – trial ends early
Disease control TerminatedThis early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…
Phase: PHASE1, PHASE2 • Sponsor: Ocellaris Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Promising breast cancer combo trial halted early – only 6 patients enrolled
Disease control TerminatedThis phase 2 trial tested repotrectinib with or without fulvestrant in people with a rare, hormone-positive, HER2-negative metastatic breast cancer called invasive lobular carcinoma. The goal was to see if the combination could control the disease after standard treatments had st…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Light therapy for stubborn eyelid lumps? tiny trial ends early
Disease control TerminatedThis study tested whether intense pulsed light (IPL) can help treat chalazion, a common eyelid lump. Only 4 adults with a fresh chalazion were enrolled, and the trial was stopped early. Because of the very small size, we cannot say if IPL works or is safe for this condition.
Phase: NA • Sponsor: Lumenis Be Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental drug HZN-825 tested for rare autoimmune lung complication
Disease control TerminatedThis trial tested the drug HZN-825 in 174 people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that can scar the lungs. Participants took the drug twice daily for 52 weeks to see if it helped maintain lung function and to check for side effects. The study w…
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Experimental blood cancer drug trial halted early
Disease control TerminatedThis study tested a new drug called SAR443579 in adults and children with certain blood cancers that had come back or not responded to treatment. The goal was to see if the drug was safe and could shrink or control the cancer. The trial was stopped early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Hizentra shows promise for rare muscle and skin disease
Disease control TerminatedThis study tested a medicine called Hizentra (IgPro20) in 134 adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. The goal was to see if weekly shots under the skin could improve symptoms better than a placebo. The study was stopped early, but res…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pill for eczema shows promise in early trial – but study halted
Disease control TerminatedThis study tested an oral medication called SAR444656 in 70 adults with moderate to severe atopic dermatitis (eczema) that was not well controlled with topical treatments. Participants received one of three doses of the drug or a placebo for 16 weeks. The goal was to see if the d…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Radioactive seeds zapped tumors from the inside — but trial stopped early
Disease control TerminatedThis early study tested a device that places radioactive seeds directly into skin, mouth, or soft tissue tumors. The seeds release alpha radiation to kill cancer cells from within. Only 2 people took part before the trial was stopped, so we don't have enough information to know i…
Phase: NA • Sponsor: Alpha Tau Medical LTD. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Experimental Lymph-Node injection for skin cancer trial halted early
Disease control TerminatedThis early-phase trial tested whether giving the immunotherapy drug STI-3031 directly into the lymph nodes or vessels (using a special device) is safe for people with in-transit melanoma, a type of skin cancer that spreads through lymph channels. Only 3 people took part before th…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New eczema drug shows promise in early trial
Disease control TerminatedThis study tested a new medicine called LY3454738 in adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if it could improve skin symptoms like redness and itching. The trial included 234 participants and was stopped early. Results may help understand i…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Experimental drug XmAb27564 tested for skin conditions – trial halted early
Disease control TerminatedThis early-stage trial tested an experimental drug called XmAb27564 in 23 people with mild-to-severe plaque psoriasis or moderate-to-severe atopic dermatitis. Participants received four doses of the drug or a placebo every two weeks. The main goal was to check safety and tolerabi…
Phase: PHASE1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Promising cream for rare skin condition falls short in early trial
Disease control TerminatedThis study tested a sirolimus cream (0.2% and 0.4%) applied daily for 12 weeks to treat facial angiofibromas in children aged 2-21 with tuberous sclerosis complex. The goal was to see if the cream could safely reduce the size and redness of these skin growths. The trial was termi…
Phase: PHASE2 • Sponsor: Aucta Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Psoriasis combo therapy trial ends early: what happened?
Disease control TerminatedThis study tested whether adding low-dose methotrexate to standard anti-TNF therapy could improve and extend the response in adults with moderate to severe psoriasis. The trial planned to enroll 78 participants but was terminated early. The main goal was to see how long patients …
Phase: PHASE4 • Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Cancer-Fighting virus injected directly into tumors shows promise in early trial
Disease control TerminatedThis early-phase trial tested a new treatment called BT-001, a virus designed to infect and kill cancer cells, given alone or with the immunotherapy drug pembrolizumab. The study involved 31 people with advanced solid tumors like melanoma, lung cancer, or sarcoma that had spread.…
Phase: PHASE1, PHASE2 • Sponsor: Transgene • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Promising cancer combo trial halted early
Disease control TerminatedThis study tested a new drug called SOT101 (nanrilkefusp alfa) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo could shrink tumors. The trial was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New hope for chemo-resistant breast cancer? trial tests immune-boosting drug
Disease control TerminatedThis study looked at whether the drug abemaciclib could help people with triple negative breast cancer that didn't respond to standard chemotherapy. The goal was to see if the drug could change the tumor's immune environment to make it more attackable by the body's defenses. The …
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New transplant method shows promise for tough blood cancers
Disease control TerminatedThis study tested a bone marrow transplant using a partially matched family donor for people with blood cancers like leukemia. The goal was to see if a milder conditioning regimen and a drug called cyclophosphamide could help patients survive at least 180 days after transplant. T…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
One-Time radiation during breast surgery: can imaging pick the right patients?
Disease control TerminatedThis study looked at whether mammography and breast MRI could help identify patients with early-stage breast cancer (DCIS) who could safely receive a single dose of radiation during surgery, instead of weeks of daily radiation afterward. The goal was to avoid repeat surgeries and…
Phase: NA • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Eczema drug trial halted early: what we know
Disease control TerminatedThis study tested an experimental drug called IMG-007 in 13 adults with moderate-to-severe atopic dermatitis (eczema) who did not get enough relief from topical treatments. The main goal was to check the drug's safety, and researchers also looked at how the body processes it and …
Phase: PHASE1, PHASE2 • Sponsor: Inmagene LLC • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cream combo tested for scalp bumps in men of african descent
Disease control TerminatedThis study tested Duobrii, a prescription cream that combines a strong steroid with a retinoid, for treating early-mild acne keloidalis nuchae (AKN) — a chronic scalp condition causing bumps and scarring, mainly in men of African descent. The trial planned to enroll 15 adults wit…
Phase: PHASE3 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Promising drug trial for painful skin ulcers halted early
Disease control TerminatedThis study tested a drug called vilobelimab for people with pyoderma gangrenosum, a rare condition causing painful skin ulcers. The trial aimed to see if the drug could completely close the ulcers compared to a placebo. It included 54 adults and was stopped early, so the results …
Phase: PHASE3 • Sponsor: InflaRx GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental cell therapy targets deadly childhood brain cancer
Disease control TerminatedThis early-phase trial tested a new immunotherapy approach for children with DIPG, a rare and aggressive brain stem tumor. After standard radiation and chemotherapy, patients received special vaccines and immune cells designed to attack the tumor. The study was small (11 particip…
Phase: PHASE1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental combo for skin cancer shows early promise but study halted
Disease control TerminatedThis study tested whether adding an immune-boosting drug (NT-I7) to a standard immunotherapy (atezolizumab) could help people with advanced skin cancers like melanoma, Merkel cell carcinoma, and squamous cell carcinoma. The trial included 31 adults whose cancer had not responded …
Phase: PHASE1, PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Spesolimab shows promise for Long-Term control of painful hand and foot pustules
Disease control TerminatedThis study looks at the long-term safety of spesolimab for people with palmoplantar pustulosis, a chronic skin condition causing painful pustules on hands and feet. Participants who benefited from spesolimab in earlier trials can continue treatment for up to 5 years, with monthly…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug trial ends early
Disease control TerminatedThis early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug trial for painful skin condition halted early
Disease control TerminatedThis study tested a drug called izokibep for people with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps. The trial aimed to see if izokibep could reduce skin abscesses and inflammation. It included 258 adults who had not responded to o…
Phase: PHASE3 • Sponsor: ACELYRIN Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Promising lymphoma combo trial halted after just 8 patients
Disease control TerminatedThis early-phase trial tested two lab-made antibodies, magrolimab and mogamulizumab, together in people with a type of T-cell lymphoma (mycosis fungoides or Sezary syndrome) that had returned or stopped responding to prior treatments. The goal was to find the best dose and see if…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New wound therapy for rare skin disease shows early promise
Disease control TerminatedThis study tested a treatment for pyoderma gangrenosum, a rare skin condition that causes painful, hard-to-heal ulcers. Researchers used a special wound covering made from donated placenta tissue (EpiFix) followed by skin grafts. The study was stopped early after only 5 people en…
Phase: PHASE4 • Sponsor: Louisiana State University Health Sciences Center in New Orleans • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental drug targets rare fat Disorder's metabolic woes
Disease control TerminatedThis phase 2 trial tested a drug called REGN4461 (mibavademab) in 20 people with familial partial lipodystrophy, a rare condition causing abnormal fat distribution and metabolic problems. The study aimed to see if the drug could lower high triglycerides and improve blood sugar co…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug targets genetic weakness in tough cancers
Disease control TerminatedThis phase 2 trial tested the drug tovorafenib (DAY101) in 23 people aged 12 and older with recurrent or progressive solid tumors that have specific genetic changes in the MAPK pathway. The goal was to see how many patients' tumors shrank or disappeared. The study was terminated …
Phase: PHASE2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New eczema drug abrocitinib tested in everyday use
Disease control TerminatedThis study looked at how well the drug abrocitinib works for adults with moderate to severe atopic dermatitis (eczema) in real-world clinics in Germany. Researchers tracked 112 participants for up to 12 months to see if their skin cleared or improved. The goal was to understand t…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Cancer drug study halted early: what we know
Disease control TerminatedThis study tested a new drug called LB101 in 25 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and see if the drug shrank tumors. The study was terminated early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Triple therapy for melanoma: hope or hype?
Disease control TerminatedThis phase 3 study tested whether adding an immunotherapy drug (spartalizumab) to two targeted therapy drugs (dabrafenib and trametinib) works better than the targeted drugs alone for people with advanced BRAF V600 mutant melanoma. The trial enrolled 568 participants but was term…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 18:27 UTC
-
Promising ichthyosis drug trial stalls after just 5 patients
Disease control TerminatedThis study tested a drug called imsidolimab (ANB019) in people with ichthyosis, a condition that causes dry, scaly, and red skin. The trial aimed to see if the drug could improve skin symptoms compared to a placebo. However, the study was stopped early and only enrolled 5 partici…
Phase: PHASE2 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 17:50 UTC
-
Experimental tumor injection trial halted early
Disease control TerminatedThis early-stage trial tested an experimental drug called SAR441000, injected directly into tumors, either alone or with another drug (cemiplimab) given through a vein. The study aimed to find a safe dose and see if the combination could shrink tumors in people with advanced soli…
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 15:44 UTC
-
Super-Fine ultrasound could spare melanoma patients a second surgery
Diagnosis TerminatedThis trial investigates whether a new, ultra-high-frequency ultrasound device can accurately measure the depth of skin melanomas before surgery. Currently, doctors must remove the tumor, measure its depth under a microscope, and then often perform a second surgery to remove more …
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Can smartphone cameras spot skin cancer as well as a dermatologist?
Diagnosis TerminatedThis study tested three portable imaging systems (MoleMapper, Visiomed, and confocal microscopy) to see how well they could detect melanoma compared to a dermatologist's exam. Seventeen people with suspicious moles participated. The goal was to find out if these devices could acc…
Phase: NA • Sponsor: OHSU Knight Cancer Institute • Aim: Diagnosis
Last updated Jun 27, 2026 12:05 UTC
-
AI mole checker tested at home – but trial stops early
Diagnosis TerminatedThis study tested whether a device called the Sklip System, which uses artificial intelligence, could help people at home decide if a mole might be skin cancer. Only one person took part before the study was stopped early. The goal was to see if the AI could match or beat standar…
Phase: NA • Sponsor: OHSU Knight Cancer Institute • Aim: Diagnosis
Last updated Jun 27, 2026 08:07 UTC
-
New PET tracer aims to light up inflammation in joint and muscle diseases
Diagnosis TerminatedThis early-phase study tested a new radioactive imaging drug called 11C-MC1 to see if it can help detect inflammation in people with rheumatoid arthritis or idiopathic inflammatory myopathy, as well as in healthy volunteers. Participants received PET/CT scans after an injection o…
Phase: PHASE1 • Sponsor: National Institute of Mental Health (NIMH) • Aim: Diagnosis
Last updated Jun 26, 2026 18:25 UTC
-
Skin-Saving paste for cancer radiation falls short in tiny trial
Prevention TerminatedThis study tested whether Alkagin paste could prevent skin damage in patients receiving radiation for anal, rectal, or gynecological cancers. Only 2 people enrolled before the trial was stopped early. Because of this, we cannot draw any reliable conclusions about the paste's effe…
Phase: PHASE2 • Sponsor: Sir Mortimer B. Davis - Jewish General Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:32 UTC
-
Smart wheelchair cushion aims to stop pressure sores
Prevention TerminatedThis study tested a special seat cushion (GASPARD®) that measures pressure and sends alerts to a smartphone to help prevent pressure sores in people with spinal cord injuries. The trial included 134 participants who used manual wheelchairs. Unfortunately, the study was terminated…
Phase: NA • Sponsor: Nantes University Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:10 UTC
-
Porphyria prevention study halted early – little data to go on
Prevention TerminatedThis small phase 2 trial tested whether the drug Panhematin could prevent acute attacks in people with certain types of porphyria. Only 13 participants were enrolled before the study was terminated early. Researchers tracked attacks and serious side effects, but the limited data …
Phase: PHASE2 • Sponsor: The University of Texas Medical Branch, Galveston • Aim: Prevention
Last updated Jun 27, 2026 09:00 UTC
-
Breast cancer prevention study halted: tamoxifen pill vs. gel tested
Prevention TerminatedThis study aimed to see if a tamoxifen skin gel could work as well as the pill to lower breast cancer risk in women with certain high-risk breast conditions. The trial enrolled 65 women and compared short-term changes in breast tissue. However, the study was terminated early, so …
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Jun 27, 2026 08:13 UTC
-
Nail psoriasis injection study halted after just one person
Symptom relief TerminatedThis study tested whether injecting methotrexate directly into the nail area could improve nail psoriasis symptoms like pitting and discoloration. Only one person enrolled before the trial was stopped early. The goal was to measure changes in nail appearance using a severity scor…
Phase: PHASE4 • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
WaterPik for your head? study tests scalp massager for flakes and hair loss
Symptom relief TerminatedThis study tested a WaterPik-like device to massage and clean the scalp in people with dandruff, seborrheic dermatitis, or hair loss. Only 2 people took part before the study was stopped early. The goal was to see if the device could reduce flaking and redness.
Phase: NA • Sponsor: University of Minnesota • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Laser zaps belly skin – but trial fizzles out
Symptom relief TerminatedThis small study tested a special laser (violet and green light) to see if it could tighten loose skin on the belly. Only 9 people signed up, and the study was stopped early. Researchers planned to compare before-and-after photos to judge improvement, but the tiny size and early …
Phase: NA • Sponsor: Erchonia Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Can a sticky patch make your scar look better?
Symptom relief TerminatedThis study tested whether a silicone adhesive dressing called Embrace can improve the look of scars after skin surgery. Half of each surgical wound was treated with the device, the other half with standard care. The trial was stopped early, so results are limited, but the goal wa…
Phase: NA • Sponsor: University of California, Davis • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Laser zaps acne? small trial fizzles out
Symptom relief TerminatedThis study tested whether a fractional carbon dioxide laser can improve moderate to severe acne in adults aged 18 to 40. Participants received up to 3 laser treatments and were followed for changes in blemish count and skin severity. The trial was terminated early and only enroll…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Eczema cream study halted after just 3 volunteers
Symptom relief TerminatedThis small study tested an over-the-counter cream for atopic dermatitis (eczema) in just 3 people. Researchers looked at skin bacteria, hydration, and barrier function to see if the cream helped. The study was terminated early, so results are very limited.
Phase: PHASE1 • Sponsor: Good Molecules, LLC • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
New drug offers hope for severe itch from skin lumps
Symptom relief TerminatedThis study tested the drug upadacitinib in 5 adults with moderate-to-severe prurigo nodularis, a condition causing very itchy skin bumps. The main goal was to see if it reduces itching by at least 4 points on a scale after 12 weeks. The study was stopped early, so results are lim…
Phase: PHASE4 • Sponsor: Psoriasis Treatment Center of Central New Jersey • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Hot flash relief drug studied in breast cancer patients
Symptom relief TerminatedThis study tested fezolinetant, a drug that blocks a brain receptor involved in temperature control, to see if it reduces hot flashes and night sweats in women with breast cancer taking hormone therapy. Nine participants were enrolled before the trial was stopped early. The goal …
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Can a blood injection boost carpal tunnel surgery results?
Symptom relief TerminatedThis study looked at whether adding platelet-rich plasma (PRP) to standard carpal tunnel release surgery helps people with severe carpal tunnel syndrome. The trial planned to enroll 15 adults with severe nerve damage. It compared surgery with PRP to surgery alone. The study was t…
Phase: NA • Sponsor: Michael Fredericson, MD • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Experimental combo therapy for brain metastases shows early safety signals
Symptom relief TerminatedThis early-stage trial tested whether adding a device that creates electric fields (NovoTTF-200M) to standard radiation and immunotherapy is safe for people with melanoma that has spread to the brain. Only one person took part before the study was stopped early. The main goal was…
Phase: PHASE1 • Sponsor: Emory University • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New moisturizer combo tested for dry skin relief
Symptom relief TerminatedThis study tested whether a daily serum and cream could improve skin hydration and reduce redness in people with dry skin. Twenty-one adults applied the products for 14 days. The researchers measured skin moisture and redness before and after treatment to see if the products help…
Phase: NA • Sponsor: SCF Pharma • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Omega-3 skin cream shows promise for eczema relief in small study
Symptom relief TerminatedThis early study tested whether a daily omega-3 serum and cream could ease eczema symptoms and change the balance of bacteria on the skin. Seven adults with eczema applied the products for six weeks and reported their symptom severity using a questionnaire. The study also checked…
Phase: NA • Sponsor: SCF Pharma • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Psoriasis drug trial for sensitive areas halted early
Symptom relief TerminatedThis study tested the drug deucravacitinib (SOTYKTU) in 130 people with psoriasis on the palms, soles, and genitals. The goal was to see if it improves skin clearance and reduces symptoms. The trial was terminated early, so final results are limited.
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
Laser hope for scars and scleroderma fizzles in tiny trial
Symptom relief TerminatedThis study tested whether a special laser could improve scars and skin hardening from scleroderma. Only 6 people took part, and the study was stopped early. Researchers measured scar changes using a standard scale, but the small size and early termination mean we cannot draw firm…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
New eczema pill shows promise in Mid-Stage trial
Symptom relief TerminatedThis study tested an experimental daily pill called RPT193 for adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve with topical creams. The goal was to see if it reduces skin redness, swelling, and itchiness over 16 weeks. The trial involved 229 particip…
Phase: PHASE2 • Sponsor: RAPT Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Can a laser make hair grow? small study tests skin rejuvenation for bald spots
Symptom relief TerminatedThis study tested whether a laser treatment used for skin rejuvenation could help grow hair in people with alopecia (hair loss) on the scalp. Only 5 people were enrolled before the study was stopped early. Each person had half their scalp treated with a laser and the other half l…
Phase: NA • Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
Can a simple cream stop radiation burns? early trial halted
Symptom relief TerminatedThis study tested a cream called dermaprazole (a form of esomeprazole) to see if it could prevent or reduce skin burns caused by radiation therapy in women who had mastectomy for breast cancer. Only 3 women were enrolled before the trial was stopped early. The goal was to check s…
Phase: PHASE1, PHASE2 • Sponsor: Baylor College of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Shock therapy for lungs? tiny TENS trial fizzles out
Symptom relief TerminatedThis study looked at whether a gentle electrical stimulation device (TENS) placed on the skin could help people with COPD exercise longer after a serious flare-up. The plan was to compare exercise time with and without TENS in a small group of patients. However, the study was sto…
Phase: NA • Sponsor: Groupe Hospitalier du Havre • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
New wound pump shows promise for stubborn leg ulcers
Symptom relief TerminatedThis study tested whether a single-use negative pressure wound therapy system (PICO) helps heal hard-to-treat venous leg ulcers better than standard care. About 142 adults with leg ulcers that had lasted at least 6 weeks took part. The main goal was to see if more ulcers healed c…
Phase: NA • Sponsor: Smith & Nephew, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
New pill for stubborn hives shows promise, but trial halted early
Symptom relief TerminatedThis Phase 2 trial tested an experimental drug called EP262 in 113 people with chronic spontaneous urticaria (long-lasting hives with no clear cause). Participants took either EP262 or a placebo daily for 6 weeks, while continuing their usual antihistamines. The study aimed to se…
Phase: PHASE2 • Sponsor: Escient Pharmaceuticals, Inc • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
Eczema cream aims to end sleepless nights
Symptom relief TerminatedThis study tested a prescription cream called ruxolitinib on adults with mild-to-moderate eczema who had trouble sleeping because of their condition. The goal was to see if the cream could help them sleep longer and better. The study was stopped early, but it involved 47 particip…
Phase: PHASE4 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
New hope for painful skin condition? study cut short
Symptom relief TerminatedThis study tested a new drug, SAR444656, in 70 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing boils and abscesses. Participants took the drug or a placebo for 16 weeks to see if it reduced the number of inflamed nodules and abscesse…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Hair loss hope? supplement tested in men, but study stopped early
Symptom relief TerminatedThis study tested a dietary supplement made from plant extracts to see if it could help men aged 40 to 65 with thinning hair. The trial was planned to last 9 months and involved 155 men, but it was terminated early. Researchers aimed to measure hair growth and quality compared to…
Phase: NA • Sponsor: Nutraceutical Wellness Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
New wound vacuum dressing shows promise in small study
Symptom relief TerminatedThis study tested a new type of wound vacuum dressing on 7 people with chronic or acute wounds. The goal was to see if the dressing helps wounds heal or get better. The study was stopped early, so results are limited.
Sponsor: Smith & Nephew, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Experimental shot for Cold-Triggered hives tested, but trial stopped early
Symptom relief TerminatedThis early-stage trial tested a single dose of a drug called briquilimab in 27 adults with chronic hives caused by cold or friction that did not improve with standard allergy pills. The main goal was to check safety and see if the drug could reduce symptoms. However, the trial wa…
Phase: PHASE1, PHASE2 • Sponsor: Jasper Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
Cancer rash drug trial halted early – little known
Symptom relief TerminatedThis small, early-stage trial tested a drug called imsidolimab for treating acne-like skin rashes that can occur in cancer patients taking certain targeted therapies. Only 4 people were enrolled before the study was stopped. Because of the very small size and early termination, w…
Phase: PHASE2 • Sponsor: Vanda Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Contact lens coating replenisher tested for rare eye conditions
Symptom relief TerminatedThis study tested a monthly solution called Tangible Boost that is meant to restore a special coating on contact lenses. The goal was to see if it could improve comfort and vision in people with severe dry eye from Stevens-Johnson syndrome, Sjogren's syndrome, or graft-versus-hos…
Phase: NA • Sponsor: Tangible Science • Aim: Symptom relief
Last updated Jun 26, 2026 18:06 UTC
-
Rare skin disease study seeks to understand netherton syndrome
Knowledge-focused TerminatedThis study aimed to collect real-world data on Netherton Syndrome, a rare genetic skin disorder. Researchers planned to follow 4 participants over 52 weeks, measuring skin severity and other symptoms. The study was terminated early, so results are limited.
Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Skin microbes linked to vitiligo and immunotherapy reactions in melanoma patients
Knowledge-focused TerminatedThis study explores whether the community of bacteria living on the skin (the skin microbiome) plays a role in vitiligo—a condition that causes white patches—and in side effects from anti-PD-1 immunotherapy for advanced melanoma. Researchers will collect skin swabs from people wi…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists dive into cells to unravel costello Syndrome's secrets
Knowledge-focused TerminatedThis study collects small skin samples from children aged 2 to 17 with Costello syndrome or a related condition. Researchers will analyze the cells to understand how a mutation in the HRAS gene affects energy use and mitochondria. The goal is to learn more about the disease's und…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
New radiofrequency skin treatment studied for safety
Knowledge-focused TerminatedThis study tested a radiofrequency-based treatment on the skin of healthy volunteers and people with hidradenitis suppurativa (a painful skin condition). The main goal was to see if the treatment is safe and tolerable. The study was stopped early, but it aimed to understand how t…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Gene study may explain why some breast cancers resist hormone therapy
Knowledge-focused TerminatedThis study looked at whether a specific gene mutation (HSD3B1) changes how well the hormone therapy letrozole works in postmenopausal women with early-stage, hormone-sensitive breast cancer. Researchers measured changes in tumor markers before and after treatment. The trial was e…
Phase: PHASE4 • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Yeast study in rare autoimmune disease terminated early
Knowledge-focused TerminatedThis study aimed to compare the types of Candida yeast found in patients with two forms of autoimmune polyendocrinopathy, a rare condition where the immune system attacks multiple glands. Researchers planned to collect samples from the mouth and urine of 7 participants to see how…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Scientists hunt for blood clues to tame unpredictable swelling attacks
Knowledge-focused TerminatedThis study aimed to find biomarkers (measurable substances in the blood) that could help doctors diagnose bradykinin angioedema and predict how severe attacks might be. The condition causes sudden, unpredictable swelling, and current tests don't work well for all types. Researche…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Hidden fat lumps may sabotage insulin: new study investigates
Knowledge-focused TerminatedThis study looked at whether small, hard-to-see fat lumps under the skin (called subclinical lipohypertrophy) change how insulin is absorbed in people with diabetes. Researchers planned to enroll 20 adults with type 1 or type 2 diabetes who use insulin and had these hidden lumps.…
Phase: NA • Sponsor: University of British Columbia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Genetic test aims to improve breast cancer decisions for black and hispanic women
Knowledge-focused TerminatedThis study looked at whether adding a polygenic risk score (a genetic test) to standard breast cancer risk tools helps African American and Hispanic women make better decisions about screening and prevention. Researchers enrolled 19 women at higher risk for breast cancer. The stu…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Superhero training for food allergy safety falls short
Knowledge-focused TerminatedThis study aimed to help children aged 6-8 from low-income families learn how to avoid foods they are allergic to. The program used fun, hands-on activities to teach safety skills. The study was stopped early, so we don't have clear results on whether it worked.
Phase: NA • Sponsor: Kent State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Microscope inside the lungs reveals hidden damage in two diseases
Knowledge-focused TerminatedThis study used a special microscope on the tip of a thin tube (bronchoscope) to look at the smallest blood vessels in the lungs of people with scleroderma or emphysema. The goal was to see how these vessels change in each disease. Only 9 patients were enrolled before the study w…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Skin cancer surveillance study ends early after just one patient
Knowledge-focused TerminatedThis study aimed to see if regular ultrasound scans of lymph nodes could detect the spread of high-risk skin cancer on the head or neck earlier than usual. It planned to enroll patients with aggressive tumors or weakened immune systems. However, the study was terminated after onl…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Scientists hunt for hidden family genes behind painful skin disease
Knowledge-focused TerminatedThis study aimed to find a genetic link or family trait that connects people with Hidradenitis Suppurativa (HS), a painful skin condition. Researchers collected blood or saliva samples from 97 participants, including affected individuals and their family members, to analyze DNA f…
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Tiny study tests oxygen measurement in skin cancers
Knowledge-focused TerminatedThis study tested a method called EPR oximetry to measure oxygen levels in skin tumors. Only 3 people took part before the study was stopped early. The goal was to see if this technique could track how tumors respond to oxygen therapy and standard cancer treatments.
Phase: NA • Sponsor: West Virginia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Insulin's hidden role in psoriasis uncovered
Knowledge-focused TerminatedThis study looked at how insulin works in the skin of people with plaque psoriasis who are also overweight or have prediabetes. Researchers took small skin samples from both psoriasis patches and healthy skin to measure insulin activity. The goal was to understand if insulin acts…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Eczema Drug's skin secrets under the microscope
Knowledge-focused TerminatedThis study looked at how the drug tralokinumab affects the skin of people with moderate to severe atopic dermatitis (eczema). Researchers measured drug levels and immune changes in skin samples after 16 weeks of treatment. The goal was to better understand how the drug works, whi…
Phase: PHASE2, PHASE3 • Sponsor: University of Zurich • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Liver study for cancer drug stopped early – only 2 people joined
Knowledge-focused TerminatedThis study looked at how moderate or severe liver problems change the amount of the cancer drug oral azacitidine in the blood. It was designed for adults with certain blood cancers. The study was stopped early after only 2 people enrolled, so the results are very limited.
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Sleep apnea study probes fat inflammation – CPAP may help
Knowledge-focused TerminatedThis study aimed to see if using a CPAP machine (a device that helps breathing during sleep) reduces inflammation in fat tissue for people with sleep apnea, both obese and non-obese. Researchers planned to compare CPAP treatment to a placebo in 40 men. The study was stopped early…
Phase: NA • Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Experimental eczema drug tested in healthy people – but trial halted
Knowledge-focused TerminatedThis was a very early (Phase 1) study to check the safety of an experimental drug called IPG7236, taken as a pill. The study involved 63 healthy adults aged 18 to 55. The goal was to see how the body handles the drug and if it causes side effects, before testing it in people with…
Phase: PHASE1 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Filmed consultations aim to decode eczema discomfort in babies under 6 months
Knowledge-focused TerminatedThis study filmed consultations between dermatologists and infants under 6 months old with atopic dermatitis (eczema). Researchers analyzed the videos to identify specific behaviors that might indicate discomfort, since standard itch assessment scales don't work for babies this y…
Phase: NA • Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Eczema study sheds light on skin disease and treatment options
Knowledge-focused TerminatedThis study aimed to better understand eczema by collecting data, blood, and skin samples from 69 participants across Canada. It also compared two types of light therapy (broadband vs narrowband UVB) to see which works better for treating eczema. The study was terminated early, so…
Phase: NA • Sponsor: Women's College Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Experimental eczema drug trial halted before results
Knowledge-focused TerminatedThis early-phase study aimed to test the safety of a new drug called LY3872386 in healthy volunteers and people with atopic dermatitis (eczema). The trial was terminated early, so no meaningful data on safety or how the body processes the drug were collected. Only 18 participants…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Cancer drug tested before surgery for non-invasive breast condition
Knowledge-focused TerminatedThis study looked at whether giving the drug palbociclib before surgery could cause changes in breast tissue in people with ductal carcinoma in situ (DCIS), a very early form of breast cancer. It planned to enroll 24 participants, but was stopped early after only 17 joined. The m…
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
COVID-19 vaccine response under scrutiny in autoimmune patients
Knowledge-focused TerminatedThis study looked at how well the COVID-19 vaccine triggers an immune response in people with autoimmune or inflammatory diseases who take immunosuppressants or biologics. Researchers took blood samples before vaccination and at several points after to measure antibodies and T-ce…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:24 UTC
-
Tiny study on drug monitoring in scleroderma ends early
Knowledge-focused TerminatedThis study aimed to see if measuring the amount of mycophenolic acid in the blood could help doctors adjust the dose of mycophenolate mofetil (MMF) to better treat skin and lung problems in people with systemic sclerosis. Only 2 patients were enrolled before the study was termina…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:32 UTC